Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

NCT00383760 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Pancreatic Cancer
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions

DRUG: eribulin mesylate

Sponsor

National Cancer Institute (NCI)